333 related articles for article (PubMed ID: 26048626)
1. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
La Torre F; Muratore M; Vitale A; Moramarco F; Quarta L; Cantarini L
Rheumatol Int; 2015 Nov; 35(11):1943-7. PubMed ID: 26048626
[TBL] [Abstract][Full Text] [Related]
2. A Case Presenting with the Clinical Characteristics of Tumor Necrosis Factor (TNF) Receptor-associated Periodic Syndrome (TRAPS) without TNFRSF1A Mutations Successfully Treated with Tocilizumab.
Hosoya T; Mizoguchi F; Hasegawa H; Miura K; Koike R; Kubota T; Miyasaka N; Kohsaka H
Intern Med; 2015; 54(16):2069-72. PubMed ID: 26278305
[TBL] [Abstract][Full Text] [Related]
3. Canakinumab for the treatment of TNF-receptor associated periodic syndrome.
La Torre F; Caparello MC; Cimaz R
Expert Rev Clin Immunol; 2017 Jun; 13(6):513-523. PubMed ID: 28454496
[TBL] [Abstract][Full Text] [Related]
4. Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant.
Cantarini L; Lopalco G; Vitale A; Caso F; Lapadula G; Iannone F; Galeazzi M; Rigante D
Int J Rheum Dis; 2015 May; 18(4):473-5. PubMed ID: 25522898
[No Abstract] [Full Text] [Related]
5. [Tumor necrosis receptor associated periodic syndrome (TRAPS): State of the art].
Georgin-Lavialle S; Kone-Paut I; Delaleu J; Sarrabay G; Grateau G; Touitou I; Hentgen V
Rev Med Interne; 2018 Apr; 39(4):256-264. PubMed ID: 29525418
[TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives.
Cantarini L; Lucherini OM; Muscari I; Frediani B; Galeazzi M; Brizi MG; Simonini G; Cimaz R
Autoimmun Rev; 2012 Nov; 12(1):38-43. PubMed ID: 22884554
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profile in TNF receptor-associated periodic syndrome reveals constitutively enhanced pathways and new players in the underlying inflammation.
Borghini S; Ferrera D; Prigione I; Fiore M; Ferraris C; Mirisola V; Amaro AA; Gueli I; Zammataro L; Gattorno M; Pfeffer U; Ceccherini I
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S121-S128. PubMed ID: 27310036
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of canakinumab for mosaic tumor necrosis factor receptor associated periodic syndrome.
Terré A; Vautier M; Kahn JE; Georgin-Lavialle S; Boursier G
Eur J Intern Med; 2024 May; 123():156-158. PubMed ID: 38307733
[No Abstract] [Full Text] [Related]
9. Tumor necrosis factor receptor-associated periodic syndrome in a pediatric patient: A genetic diagnosis.
Yakhmi N; Knutsen AP
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):369-371. PubMed ID: 32376455
[No Abstract] [Full Text] [Related]
10. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.
Lopalco G; Rigante D; Vitale A; Frediani B; Iannone F; Cantarini L
Clin Rheumatol; 2015 Apr; 34(4):807-9. PubMed ID: 24609716
[TBL] [Abstract][Full Text] [Related]
11. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.
Ozen S; Kuemmerle-Deschner JB; Cimaz R; Livneh A; Quartier P; Kone-Paut I; Zeft A; Spalding S; Gul A; Hentgen V; Savic S; Foeldvari I; Frenkel J; Cantarini L; Patel D; Weiss J; Marinsek N; Degun R; Lomax KG; Lachmann HJ
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):578-586. PubMed ID: 27723279
[TBL] [Abstract][Full Text] [Related]
12. The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review.
Magnotti F; Vitale A; Rigante D; Lucherini OM; Cimaz R; Muscari I; Granados Afonso de Faria A; Frediani B; Galeazzi M; Cantarini L
Clin Exp Rheumatol; 2013; 31(3 Suppl 77):141-9. PubMed ID: 23899820
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor receptor-associated periodic fever syndrome in a 58-year-old man: caution not to discount TRAPS as a diagnosis in older patients.
Sinožić D; Toplak N; Milotić I
J Clin Rheumatol; 2011 Sep; 17(6):325-8. PubMed ID: 21869706
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome.
Tsuji S; Matsuzaki H; Iseki M; Nagasu A; Hirano H; Ishihara K; Ueda N; Honda Y; Horiuchi T; Nishikomori R; Morita Y; Mukai T
Clin Exp Immunol; 2019 Dec; 198(3):416-429. PubMed ID: 31429073
[TBL] [Abstract][Full Text] [Related]
15. Molecular and clinical spectrum of four pedigrees of TRAPS in Greece: results from a national referral center.
Nezos A; Argyropoulou OD; Klinaki E; Marketos N; Karagianni P; Eliopoulos E; Vlachoyiannopoulos P; Maritsi DN; Tzioufas AG
Rheumatology (Oxford); 2020 Jun; 59(6):1241-1246. PubMed ID: 31562507
[TBL] [Abstract][Full Text] [Related]
16. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study.
Cantarini L; Lucherini OM; Brucato A; Barone L; Cumetti D; Iacoponi F; Rigante D; Brambilla G; Penco S; Brizi MG; Patrosso MC; Valesini G; Frediani B; Galeazzi M; Cimaz R; Paolazzi G; Vitale A; Imazio M
Clin Res Cardiol; 2012 Jul; 101(7):525-31. PubMed ID: 22311714
[TBL] [Abstract][Full Text] [Related]
17. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
[TBL] [Abstract][Full Text] [Related]
18. Analysis of NLRP3, MVK and TNFRSF1A variants in adult Greek patients with autoinflammatory symptoms.
Karagianni P; Nezos A; Ioakeim F; Tzioufas AG; Moutsopoulos HM
Clin Exp Rheumatol; 2018; 36(6 Suppl 115):86-89. PubMed ID: 30418111
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.
Gentileschi S; Rigante D; Vitale A; Sota J; Frediani B; Galeazzi M; Cantarini L
Clin Rheumatol; 2017 Jul; 36(7):1687-1690. PubMed ID: 28536823
[TBL] [Abstract][Full Text] [Related]
20. The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome.
Lee SJ; Baek JY; Lee JY; Kang JM; Ahn JG
Yonsei Med J; 2024 Apr; 65(4):241-245. PubMed ID: 38515362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
